Prevention of cytomegalovirus in organ transplant recipients: Cross roads between antiviral and antitumor immunity

Transplantation

Volumn 90, Issue 4, 2010, Pages 360-361

  Singh, Nina ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GANCICLOVIR;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HOST; IMMUNITY; KIDNEY TRANSPLANTATION; NOTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VIRUS LOAD;

ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTS;

EID: 77955983030     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e7e568     Document Type: Note

References (22)

1. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cyto-megalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 2008; 8: 1.
2. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the managementof cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
3. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869.
4. Spinner ML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplatation 2010; 90: 412.
5. Lafarge X, Merville P, Cazin MC, et al. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis 2001; 184: 533.
6. Otto M, Barfield RC, Iyengar R, et al. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Im-munother 2005; 28: 73.
7. Devaud C, Bilhere E, Loizon S, et al. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 2009; 69: 3971.
8. Couzi L, Pitard V, Netzer S, et al. Common features of gammadelta T cells and CD8(+) alphabeta T cells responding to human cytomegalovirus infection in kidney transplant recipients. J Infect Dis 2009; 200: 1415.
9. Couzi L, Levaillant Y, Jamai A, et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010; 21: 181.
10. + cytotoxic T lymphocytes in liver transplant patients. Transplantation 2000; 69: 2251.
11. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83.
12. Singh N. Optimization of outcomes related to cytomegalovirus in organ transplant recipients. Transplantation 2006; 82: 15.
13. Scholz D, Arndt R, Meyer R. Evidence for an immunosuppressive activity of ganciclovir. Transplant Proc 1994; 26: 3253.
14. Heagy W, Crumpacker C, Lopez PA, et al. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991; 87: 1916.
15. Battiwalla M, Wu Y, Bajwa RP, et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 2007; 13: 765.
16. + T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant 2009; 43: 399.
17. Sun HY, Singh N, Cacciarelli TV, et al. Dysregulated expression of T-helper cell responses and susceptibility to infections in high-risk liver transplant recipients. Transpl Immunol 2008; 20: 68.
18. Kowalik TF, Wing B, Haskill JS, et al. Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection. Proc Natl Acad Sci USA 1993; 90: 1107.
19. Tong CY, Bakran A, Williams H, et al. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol 2001; 64: 29.
20. Sharma A, Rajappa M, Satyam A, et al. Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant che-moradiation: Correlation with treatment response. Int J Gynecol Cancer 2009; 19: 1269.
21. Satyam A, Singh P, BadjatiaN, et al. A disproportion of T(H)1/T(H)2 cytokines with predominance of T(H)2, in urothelial carcinoma of bladder. Urol Oncol (Epub ahead of print, October 2009).
22. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31: 787.